This year's report highlights critical areas of growth, such as obesity, oncology, and immunology treatments, and provides an overview of the significant role of AI in drug development. With revenue at the top 17 biopharma firms expected to grow at a 4.5% compound annual growth rate through 2029, drugs in the fields of immunology and obesity are two of the biggest drivers of approved product sales.

Our latest report on the biopharmaceutical landscape analyzes industry themes, market share and concentration, ESG considerations, AI in drug development, therapeutic areas, drug pricing, and more.

Download the full report now to explore the impact on biopharma market growth, including patent expirations, clinical trial advancements, and therapeutic innovations like cell and gene therapies.